nmh ventures, LLC

310 east 44 st #315
new york, new york 10017

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 19, 2014

NYS DOS ID#
4624170

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - NMH VENTURES, LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Fit City: Taking Night-Life Cue, Gyms Lower the Lights
    By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017

    Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.

    Source: NYT > Home Page
  • Mobile gaming company Scopely raises $60M
    By Anthony Ha - Thursday Jun 15, 2017

     Scopely just announced that it has raised $60 million in Series C funding. The round was led by Revolution Growth, a firm led by former AOL executives Steve Case and Ted Leonsis (AOL owns TechCrunch), which targets startups outside Silicon Valley and New York. (Scopely is headquartered in Los Angeles.) Revolution’s Donn Davis is joining Scopely’s board of directors, while… Read More

    Source: TechCrunch
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York